BMY - Mirati Therapeutics ticks higher amid Nasdaq delisting for sale to Bristol-Myers
2024-01-19 13:24:22 ET
More on Mirati Therapeutics
- Evaluating Mirati Therapeutics' CVR Value In The Wake Of The Bristol Myers Acquisition
- Mirati's Krazati gets EU conditional approval for lung cancer
- Mirati Therapeutics gains as HSR waiting period for sale to Bristol-Myers expires
- Seeking Alpha’s Quant Rating on Mirati Therapeutics
- Historical earnings data for Mirati Therapeutics
For further details see:
Mirati Therapeutics ticks higher amid Nasdaq delisting for sale to Bristol-Myers